Specification :

PT141
Molecular Formula:C50H68N14O10
Molecular Weight:1025.2
CAS No.: 32780-32-8
Sequence: Ac-Nle-(Asp-His-D-Phe-Arg-Trp-Lys)-OH
SPECIFICATIONS:
1 .Appearance :White powder
2 .Water Content(Karl Fischer) :¡Ü5.0%
3 .Acetate Content(by HPLC) :¡Ü15.0%
4 .Amino Acid Composition :¡À10% of theoretical
5 .Purity(by HPLC) :¡�97.0%
6 .Single Impurity(by HPLC) :¡Ü1.0%
7 .Peptide Content(by %N) :¡�80%
8 .Assay(By Anhydrous, Acetic Acid-free) :95.0~105.0%
9 .Bacterial Endotoxins :¡Ü5EU/mg
Packing:plastic vial(dedicated for peptide packing) or glass vial, quantity according to customer's detail requirement.
Storage:a cool(2~8 degree C) & dry place protected from light, keep package close when not in use.
Product Detail Description
PT-141 (Bremelanotide) is the first of a new class of drugs called melanocortin agonists being developed to treat sexual dysfunction. The mechanism of action of PT-141 (Bremelanotide) may offer significant safety and efficacy benefits over currently available products because it acts on the pathway that controls sexual function without acting directly on the vascular system. Clinical data indicates that PT-141 (Bremelanotide) may be effective in treating a broad range of patients suffering from ED. The nasal formulation of PT-141 (Bremelanotide) being developed is as convenient as oral treatments, is more patient-friendly than invasive treatments for ED, such as injections and trans-urethral pellets, and appears to result in a rapid onset of action.